EP-262 inhibits agonist-induced mast cell degranulation and vascular permeability in vivo
Feb. 27, 2023
At the ongoing AAAAI meeting in San Antonio, researchers from Escient Pharmaceuticals Inc. presented preclinical data for the Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist EP-262, being evaluated as a novel therapeutic approach for mast cell-mediated diseases. In vitro, EP-262 acted as a potent and highly selective antagonist of MRGPRX2, which inhibited MRGPRX2 activation induced by a wide variety of agonists.